Azilsartan medoxomil

(Edarbi®)

Edarbi®

Latest News

loading GIF

Drug updated on 6/10/2024

Dosage FormTablet (oral; 40 mg and 80 mg)
Drug ClassAngiotensin II receptor blockers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of hypertension in adults to lower blood pressure, either alone or in combination with other antihypertensive agents.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Azilsartan medoxomil (Edarbi) is indicated for the treatment of hypertension in adults to lower blood pressure, either alone or in combination with other antihypertensive agents. It has demonstrated superior efficacy in reducing both office systolic and diastolic blood pressure compared to many other angiotensin-receptor blockers (ARBs), including versions of valsartan, irbesartan, olmesartan, and telmisartan.
  • Five systematic reviews/meta-analyses provided comprehensive insights into the safety and effectiveness of azilsartan medoxomil as an antihypertensive agent.
  • In a Japanese hypertensive population specifically, azilsartan showed a more favorable efficacy profile in reducing systolic and diastolic blood pressure compared to other ARBs according to one study.
  • The safety evaluation revealed that azilsartan medoxomil alone or combined with chlorthalidone was effective at lowering blood pressure while maintaining an acceptable safety profile. Commonly reported side effects included dizziness, headache, and fatigue, but these were considered manageable despite its potent antihypertensive effects.
  • Combination therapy involving Edarbi (azilsartan medoxomil) proved efficacious for patients suffering from chronic kidney disease along with hypertension. This combination also showcased superiority over some others regarding adherence rates among patients.
  • When comparing ARB-Amlodipine combinations within an Asian population group, it was found that Azilsartan-Amlodipine resulted in significantly higher treatment response than monotherapy or any other ARB-Amlodipine combinations; however, Telmisartan-Amlodipine had fewer adverse events reported.

Product Monograph / Prescribing Information

Document TitleYearSource
Edarbi (azilsartan medoxomil) Prescribing Information.2022Azurity Pharmaceuticals Inc., Worburn, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines